Drug Profile

Polidocanol - Leios Therapeutics

Alternative Names: 10XB 101

Latest Information Update: 02 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator 10xBio
Developer Leios Therapeutics
Class Obesity therapies; Polyethylene glycols; Sclerosants; Small molecules; Vascular disorder therapies
Mechanism of Action Endothelial cell modulators; Vascular disrupting agents

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Phase II Adipose tissue disorders; Obesity

Most Recent Events

26 Jan 2026 10xBio is now called Leios Therapeutics (Leios Therapeutics website, January 2026)
26 Jan 2026 BNC Korea in-licenses polidocanol from Leios Therapeutics
22 Jan 2025 10xBio completes a phase-II clinical trials in Adipose-tissue-disorders (In adults) in USA (SC) (NCT05760248)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com